Key result
This review summarizes the rationale and use of beta-blockers as a therapeutic strategy in patients with severe heart failure.
Why the study?
Does beta-blocker therapy improve outcomes in patients with severe heart failure?
Does beta-blocker therapy improve outcomes in patients with severe heart failure?
This review summarizes the rationale and use of beta-blockers in patients with severe heart failure, an area where controversy exists compared to mild-to-moderate heart failure.
May inform beta-blocker use in severe HF amid controversy; leaves open need for dedicated RCTs to confirm outcomes.
The medical management of heart failure has undergone remarkable progress in the past 10 years. The paradigm shift is toward long-term reparative strategies that help in altering the biologic properties of the failing heart. Together with angiotensin-converting enzyme inhibitors, beta blockers have emerged as standard therapy for heart failure, especially for patients with mild to moderate heart failure. Since most of the clinical trials demonstrating the benefits of betablockers have been done in patients with mild to moderate heart failure, some controversy exists about the utility of beta-blocking agents in patients with advanced heart failure. This review will summarize the rationale and the use of beta blockers, a very challenging therapeutic strategy, in patients with severe heart failure.
No takes yet. Share an insight, caveat, or question.
Kalapura et al. (2003) conducted a review in Severe heart failure. Beta blockers was evaluated. This review summarizes the rationale and use of beta-blockers as a therapeutic strategy in patients with severe heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: